CD274 and neoplasm: Advanced or metastatic NSCLC; measurable disease per RECIST v1.1; adequate hematological; end-organ function; provided tumor specimens for central PD-L1 testing on formalin-fixed paraffin-embedded sections before enrolment; aged ≥ 18; ECOG PS of 0 or 1.